The objective of this study is to assess and quantify noncancer causes of death after a breast cancer diagnosis. Among 183,002 of 754,270 patients with breast cancer (24.3%) who die during the follow…
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate…
The safety and efficacy of cladribine, idarubicin, and cytarabine was evaluated in a phase 2 trial of 66 patients with relapsed and/or refractory acute myeloid leukemia.…
There are multiple distinct longitudinal trajectories of cancer-related cognitive impairment (CRCI) and these may be influenced by social determinants of health such as education and…
This retrospective, observational medical record review of patients with acute myeloid leukemia in remission after induction therapy and treated with oral azacitidine (oral-AZA) in Canada…
Residing in a more contemporary redlined neighborhood (location-based mortgage discrimination) was associated with an increased risk of all-cause mortality among Black and White men diagnosed…
The integration of multidisciplinary triage and referral systems in oncology care represents a critical step toward bridging the gap between evidence-based exercise recommendations and clinical…
This graph illustrates Kaplan–Meier curves of overall survival in patients with myeloid neoplasms who have cohesin mutations with and without coexisting SRSF2 mutation. In patients with…
Cancer Cachexia Resources for Healthcare Professionals This educational resource is intended to provide healthcare professionals with the tools to aid in the effective management of…
In 2024, therapeutic breakthroughs for small cell lung cancer have led to meaningful improvements for patients, offering potential for long-term survival. Here, the authors report…
The safety and efficacy of cladribine, idarubicin, and cytarabine was evaluated in a phase 2 trial of 66 patients with relapsed and/or refractory acute myeloid leukemia.…
